Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH-7
2024-517431-43-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and chronic low back pain (CLBP) comparing Retatrutide once weekly with Placebo once weekly (2 arms). Primary endpoints: Change from baseline in weekly average pain intensity numeric rating scale (API-NRS) score and Percent change from baseline in body weight. Started Apr 2025; status: completed.
02
Drugs
03
Conditions
obesityOverweightchronic low back pain (CLBP)
Beyond the preview
Go deeper on 2024-517431-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517431-43-00.